Compile Data Set for Download or QSAR
Report error Found 81 Enz. Inhib. hit(s) with all data for entry = 10586
TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552615(WO2022101377, Example 14)
Affinity DataIC50: 0.400nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552651(WO2022101377, Example 50)
Affinity DataIC50: 0.5nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552674(WO2022101377, Example 73)
Affinity DataIC50: 0.700nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552632(WO2022101377, Example 31)
Affinity DataIC50: 1.10nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552624(WO2022101377, Example 23)
Affinity DataIC50: 1.30nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552611(WO2022101377, Example 10)
Affinity DataIC50: 1.30nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552617(WO2022101377, Example 16)
Affinity DataIC50: 1.40nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552639(WO2022101377, Example 38)
Affinity DataIC50: 1.40nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552616(WO2022101377, Example 15)
Affinity DataIC50: 1.70nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552629(WO2022101377, Example 28)
Affinity DataIC50: 1.70nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552650(WO2022101377, Example 49)
Affinity DataIC50: 1.90nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552613(WO2022101377, Example 12)
Affinity DataIC50: 1.90nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552646(WO2022101377, Example 45)
Affinity DataIC50: 1.90nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552625(WO2022101377, Example 24)
Affinity DataIC50: 2nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552635(WO2022101377, Example 34)
Affinity DataIC50: 2.10nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552652(WO2022101377, Example 51)
Affinity DataIC50: 2.20nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552644(WO2022101377, Example 43)
Affinity DataIC50: 2.60nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552667(WO2022101377, Example 66)
Affinity DataIC50: 2.70nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552618(WO2022101377, Example 17)
Affinity DataIC50: 2.80nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552634(WO2022101377, Example 33)
Affinity DataIC50: 2.80nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552638(WO2022101377, Example 37)
Affinity DataIC50: 2.90nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552637(WO2022101377, Example 36)
Affinity DataIC50: 3nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552620(WO2022101377, Example 19)
Affinity DataIC50: 3nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552619(WO2022101377, Example 18)
Affinity DataIC50: 3.10nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552608(WO2022101377, Example 7)
Affinity DataIC50: 3.60nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552636(WO2022101377, Example 35)
Affinity DataIC50: 3.80nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552626(WO2022101377, Example 25)
Affinity DataIC50: 4.30nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552621(WO2022101377, Example 20)
Affinity DataIC50: 4.5nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552627(WO2022101377, Example 26)
Affinity DataIC50: 4.90nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552623(WO2022101377, Example 22)
Affinity DataIC50: 5.30nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552628(WO2022101377, Example 27)
Affinity DataIC50: 5.5nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552647(WO2022101377, Example 46)
Affinity DataIC50: 6.30nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552605(WO2022101377, Example 4)
Affinity DataIC50: 6.80nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552673(WO2022101377, Example 72)
Affinity DataIC50: 8.10nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552606(WO2022101377, Example 5)
Affinity DataIC50: 8.20nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552622(WO2022101377, Example 21)
Affinity DataIC50: 9.10nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552666(WO2022101377, Example 65)
Affinity DataIC50: 11nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552642(WO2022101377, Example 41)
Affinity DataIC50: 11nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552648(WO2022101377, Example 47)
Affinity DataIC50: 12nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552631(WO2022101377, Example 30)
Affinity DataIC50: 12nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552649(WO2022101377, Example 48)
Affinity DataIC50: 15nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552603(WO2022101377, Example 2)
Affinity DataIC50: 30nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552633(WO2022101377, Example 32)
Affinity DataIC50: 34nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552610(WO2022101377, Example 9)
Affinity DataIC50: 34nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552670(WO2022101377, Example 69)
Affinity DataIC50: 35nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552645(WO2022101377, Example 44)
Affinity DataIC50: 41nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552612(WO2022101377, Example 11)
Affinity DataIC50: 53nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552609(WO2022101377, Example 8)
Affinity DataIC50: 55nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552640(WO2022101377, Example 39)
Affinity DataIC50: 60nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

TargetPlatelet-activating factor receptor(Human)
Boehringer Ingelheim International

WIPO
LigandPNGBDBM552630(WO2022101377, Example 29)
Affinity DataIC50: 69nMAssay Description:USING AN ENDPOINT ASSAY HEK293 cells overexpressing human PAFR (produced in-house) are seeded into a Poly-D-Lysine coated 384 well white cell culture...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/7/2022
Entry Details
WIPO WO2022101377

Displayed 1 to 50 (of 81 total ) | Next | Last >>
Jump to: